Sedentarism, Physical Activity, Steps, and Neurotrophic Factors in Obese Children

Jose Mora-Gonzalez1, Jairo H Migueles1, Irene Esteban-Cornejo1,2

  • 1PROFITH "PROmoting FITness and Health through physical activity" Research Group, Sport and Health University Research Institute (iMUDS), Department of Physical and Sports Education, Faculty of Sports Science, University of Granada, Granada, SPAIN.

Insights

Physical activity (PA) in children with overweight/obesity is linked to higher brain-derived neurotrophic factor (BDNF) levels. Slow walking cadences may also increase BDNF, suggesting potential benefits for neurotrophic factors.

Area of Science:

  • Pediatric Obesity Research
  • Neuroscience
  • Exercise Physiology

Background:

  • Childhood overweight and obesity are significant public health concerns.
  • Neurotrophic factors, like BDNF, play crucial roles in neuronal growth and survival.
  • Understanding modifiable behaviors influencing neurotrophic factors is vital for intervention.

Purpose of the Study:

  • To investigate the relationship between sedentary time, physical activity (PA), and step-related behaviors with neurotrophic growth factors in children.
  • To explore associations with brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and insulin growth factor-1 (IGF-1).

Main Methods:

  • 97 children (8-11 years) with overweight/obesity participated.
  • Accelerometers measured sedentary time, PA (light, moderate, vigorous, MVPA), and step cadences.
  • Plasma levels of BDNF, VEGF, and IGF-1 were quantified.

Main Results:

  • Moderate PA and moderate-to-vigorous PA (MVPA) were positively associated with BDNF.
  • Light PA showed a positive association with BDNF and VEGF, but this was not consistent across measurement sites.
  • Time spent in slow walking cadence bands (40-79 steps/min) was positively associated with BDNF.

Conclusions:

  • Physical activity, particularly moderate intensity, is positively related to BDNF in children with overweight/obesity.
  • Specific slow walking cadences may contribute to increased BDNF levels.
  • Further exercise-based randomized controlled trials are recommended to confirm these findings.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
144
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
210
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
184